D. R. Cox, Regression models and life-tables

, Discussion on Professor Cox's Paper, Journal of the Royal Statistical Society: Series B (Methodological), vol.34, issue.2, pp.202-220, 1972.

M. J. Stensrud, J. M. Aalen, O. O. Aalen, and M. Valberg, Limitations of hazard ratios in clinical trials, European Heart Journal, vol.40, issue.17, pp.1378-1383, 2018.

D. H. Kim, H. Uno, and L. J. Wei, Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results, JAMA Cardiology, vol.2, issue.11, p.1179, 2017.

L. Zhao, B. Claggett, L. Tian, H. Uno, M. A. Pfeffer et al., On the restricted mean survival time curve in survival analysis, Biometrics, vol.72, issue.1, pp.215-221, 2015.

B. Claggett, M. Packer, J. J. Mcmurray, K. Swedberg, J. Rouleau et al., Estimating the Long-Term Treatment Benefits of Sacubitril?Valsartan, New England Journal of Medicine, vol.373, issue.23, pp.2289-2290, 2015.

P. Royston and M. K. Parmar, Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome, BMC Medical Research Methodology, vol.13, issue.1, p.152, 2013.

B. Claggett, J. M. Lachin, S. Hantel, D. Fitchett, S. E. Inzucchi et al., Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease, Circulation, vol.138, issue.15, pp.1599-1601, 2018.

H. Uno, B. Claggett, L. Tian, E. Inoue, P. Gallo et al., Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis, Journal of Clinical Oncology, vol.32, issue.22, pp.2380-2385, 2014.

S. Stienen, J. P. Ferreira, J. Vincent, M. Busselen, B. Li et al., Estimated Long-Term Survival With Eplerenone, Journal of the American College of Cardiology, vol.73, issue.18, pp.2357-2359, 2019.